Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 9/2023

Open Access 05-06-2023 | Prostate Cancer

Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice

Authors: Janice Kim, Kendall Freeman, Alyssa Ayala, McKay Mullen, Zijie Sun, June-Wha Rhee

Published in: Current Oncology Reports | Issue 9/2023

Login to get access

Abstract

Purpose of the Review

There have been increasing reports of cardiovascular complications of androgen deprivation therapy (ADT) leading to worse outcomes among patients with prostate cancer. While this may result from the direct effects of androgen suppression in the cardiovascular systems, there are ADT-type-specific distinct cardiovascular complications suggestive of mechanisms beyond androgen-mediated. Thus, it is critical to understand the biological and clinical impact of ADT on the cardiovascular system.

Recent Findings

Gonadotropin-releasing hormone (GnRH) agonists cause increased cardiovascular events compared to GnRH antagonists. Androgen receptor antagonists are linked to an increased risk of long QT syndrome, torsades de pointes, and sudden cardiac death. Androgen synthesis inhibitors are associated with increased rates of hypertension, atrial tachyarrhythmia, and, in rare incidences, heart failure.

Summary

ADT increases the risk of cardiovascular disease. The risk among ADT drugs differs and must be evaluated to develop a medically optimal plan for prostate cancer patients.
Literature
1.
Hu J-R, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol. 2020;40:e55–64.CrossRefPubMedPubMedCentral
2.
Okwuosa TM, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14:e000082.CrossRefPubMed
3.
Handelsman DJ. Androgen physiology, pharmacology, use and misuse. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. 2020.
4.
5.
6.
Nassar GN, Leslie SW. Physiology, Testosterone. In: StatPearls [Internet]. 2022.
7.
Davey RA, Grossmann M. Androgen receptor structure, function and biology: from bench to bedside. Clin Biochem Rev. 2016;37(1):3–15.
8.
Su JJ, Park SK, Hsieh TM. The effect of testosterone on cardiovascular disease: a critical review of the literature. Am J Mens Health. 2014;8:470–91.CrossRefPubMed
9.
Gagliano-Jucá T, Basaria S. Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol. 2019;16:555–74.CrossRefPubMed
10.
Ayaz O, et al. Long-term testosterone deficiency modifies myofilament and calcium-handling proteins and promotes diastolic dysfunction in the aging mouse heart. Am J Physiol Heart Circ Physiol. 2019;316:H768–80.CrossRefPubMed
11.
Chistiakov DA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Role of androgens in cardiovascular pathology. Vasc Health Risk Manag. 2018;14:283–90.CrossRefPubMedPubMedCentral
12.
Campelo AE, Cutini PH, Massheimer VL. Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol. 2012;213:77–87.CrossRefPubMed
13.
Tsang S, Wu S, Liu J, Wong TM. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation. Br J Pharmacol. 2008;153:693–709.CrossRefPubMed
14.
Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab. 2006;91:546–54.CrossRefPubMed
15.
Pang T, Rajapurohitam V, Cook MA, Karmazyn M. Differential AMPK phosphorylation sites associated with phenylephrine vs. antihypertrophic effects of adenosine agonists in neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2010;298:H1382-90.CrossRefPubMed
16.
17.
Golden KL, Marsh JD, Jiang Y, Brown T, Moulden J. Gonadectomy of adult male rats reduces contractility of isolated cardiac myocytes. Am J Physiol Endocrinol Metab. 2003;285:E449–53.CrossRefPubMed
18.
Guo D, et al. L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. J Cardiovasc Electrophysiol. 2007;18:196–203.CrossRefPubMed
19.
Traish AM. Benefits and health implications of testosterone therapy in men with testosterone deficiency. Sex Med Rev. 2018;6:86–105.CrossRefPubMed
20.
21.
Vigen R, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–36.CrossRefPubMed
22.
Ohlsson C, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58:1674–81.CrossRefPubMed
23.
Corti M, Lorenzetti S, Ubaldi A, Zilli R, Marcoccia D. Endocrine disruptors and prostate cancer. Int J Mol Sci. 2022;23(3):1216.
24.
Fontana F, et al. Gonadotropin-releasing hormone receptors in prostate cancer: molecular aspects and biological functions. Int J Mol Sci. 2020;21(24):9511.
25.
Melloni C, et al. Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design. JACC Cardio Oncol. 2020;2(1):70–81.
26.
27.
•• Shore ND, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382:2187–96. This phase III trial demonstrates that relugolix, an oral GnRH antagonist, reduces risk of major cardiovascular events and achieves superior testosterone suppression compared to that of leuprolide, a GnRH agonist. Provides additional insight on evaluating GnRH antagonists and agonists as treatment options for PCa patients.CrossRefPubMed
28.
29.
Bhatia N, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133:537–41.CrossRefPubMedPubMedCentral
30.
Bretagne M, et al. Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis. 2020;113:9–21.CrossRefPubMed
31.
Parker C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119–34.CrossRefPubMed
32.
Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56.CrossRefPubMed
33.
34.
35.
36.
Kim DK, et al. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study. J Cancer Res Clin Oncol. 2021;147:1217–26.CrossRefPubMed
37.
• Butler SS, et al. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: a secondary analysis of the prostate, lung, colorectal, and ovarian (PLCO) randomized controlled trial. Cancer. 2021;127:2213–21. This study concludes that the use of ADT in addition to RT, compared to RT alone, does not increase risk of cardiovascular mortality. Demonstrates conflicting data in the literature, necessitating continued investigation on the side effects of ADT.CrossRefPubMed
38.
Kintzel PE, Chase SL, Schultz LM, O’Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008;28:1511–22.CrossRefPubMed
39.
• Margel D, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019;202:1199–208. This prospective study suggests that GnRH antagonists are associated with lower risk of cardiovascular and cerebrovascular events than GnRH agonists. However, PCa patients with preexisting cardiovascular disease may have different cardiac outcomes, emphasizing the importance of a risk-benefit analysis when initiating ADT.CrossRefPubMed
40.
41.
Cicero G, DELuca R, Dorangricchia P, Dieli F. The clinical efficacy of enzalutamide in metastatic prostate cancer: prospective single-center study. Anticancer Res. 2017;37:1475–80.CrossRefPubMed
42.
Zheng X, et al. Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Medicine. 2019;98:e17748.CrossRefPubMedPubMedCentral
43.
Bretagne M, et al. Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis. 2020; 113(1):9–21.
44.
• Salem J-E, et al. Androgenic effects on ventricular repolarization: a translational study from the International Pharmacovigilance Database to iPSC-cardiomyocytes. Circulation. 2019;140:1070–80. Demonstrates that different types of ADT confer distinct side-effect profiles (eg, enzalutamide was associated with the highest rate of death, hypokalemia was most present in abiraterone). Thus, careful discussion about each ADT option is essential when determining the most appropriate treatment plan.CrossRefPubMedPubMedCentral
45.
Gheorghe GS, Hodorogea AS, Ciobanu A, Nanea IT, Gheorghe ACD. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer. Curr Oncol. 2021;28:3331–46.CrossRefPubMedPubMedCentral
46.
Moreira RB, et al. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8:84572–8.CrossRefPubMedPubMedCentral
47.
Garje R, et al. Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer. Clin Genitourin Cancer. 2020;18:e157–66.CrossRefPubMed
48.
Lin Y-H, Chen C-L, Hou C-P, Chang P-L, Tsui K-H. A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma. Acta Pharmacol Sin. 2011;32:537–42.CrossRefPubMedPubMedCentral
49.
Atta MA, Elabbady A, Sameh W, Sharafeldeen M, Elsaqa M. Is there still a role for bilateral orchidectomy in androgen-deprivation therapy for metastatic prostate cancer? Arab J Urol. 2020;18:9–13.CrossRefPubMed
50.
Chen D-Y, et al. Risk of cardiovascular ischemic events after surgical castration and gonadotropin-releasing hormone agonist therapy for prostate cancer: a nationwide cohort study. J Clin Oncol. 2017;35:3697–705.CrossRefPubMed
51.
Teoh JY, et al. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl. 2015;17:493–6.CrossRefPubMed
Metadata
Title
Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice
Authors
Janice Kim
Kendall Freeman
Alyssa Ayala
McKay Mullen
Zijie Sun
June-Wha Rhee
Publication date
05-06-2023
Publisher
Springer US
Published in
Current Oncology Reports / Issue 9/2023
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-023-01424-2

Other articles of this Issue 9/2023

Current Oncology Reports 9/2023 Go to the issue

ReviewPaper

Vascular Inflammation, Cancer, and Cardiovascular Diseases

ReviewPaper

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism

ReviewPaper

Kidney Cancer Integrative Oncology: Possible Options for Care

ReviewPaper

Pre- and Post-Microsurgical Rehabilitation Interventions and Outcomes on Breast Cancer–Related Lymphedema: a Systematic Review

ReviewPaper

Disease assessments in patients with glioblastoma

ReviewPaper

Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits